From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping

Abstract excerpt

Targeted therapies have radically altered the prognosis of patients with non-small cell lung cancer (NSCLC). Although the MET pathway was characterized in 1984, the treatment paradigm for patients with MET alterations has only recently changed. Genomic alterations in MET are found in 3%-5% of patients with NSCLC, and can include MET exon 14 (METex14) skipping, MET-activating mutations, and MET amplification....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Liver physiology and pathology
• Share to Lung Cancer Treatments and Mutations
• Share to PI3K/AKT/mTOR signaling in cancer